TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01570699

Intervention type: GENETIC
Intervention: COMT polymorphism
Description: The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity

Intervention type: GENETIC
Intervention: COMT polymorphism
Description: The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
Study: NCT01311804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: parecoxib sodium
Description: periarticular parecoxib sodium injection will be given during total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib sodium
Description: intravenous parecoxib sodium during total knee arthroplasty
Study: NCT01703832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan®
Description: 0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
Study: NCT04168788

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test for genetic analysis
Description: Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
Study: NCT01317927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, Warfarin
Description: 1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
Study: NCT01165671

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiotherapy
Description: Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
Study: NCT02830022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological explorations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological explorations
Study: NCT02268032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA 2.2 g in vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Another Androgenic Agent (VRaA)
Description: Testosterone 35 mg in vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination of 2 androgenic agents (VR2A)
Description: DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
Study: NCT01050803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FDSME group
Description: In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FDSME
Description: In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
Study: NCT00912353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Single Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Oral
Study: NCT03969953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Rivaroxaban is an orally administered selective direct factor Xa inhibitor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rivaroxaban matched placebo
Study: NCT01424644

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Description: All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Description: All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®.
Study: NCT01655628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)
Description: A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GC chemotherapy (Gemcitabine, Cisplatin)
Description: A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
Study: NCT01674582

Intervention type: OTHER
Group type: OTHER
Intervention: MRI, neuropsychological evaluation, blood sampling
Description: MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years.
Study: NCT01179048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Study: NCT01832701

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: coffee versus placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: maltodextrine with caffeine
Study: NCT01091090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral
Description: Cognitive behavioral intervention for smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study: NCT01864330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo®
Description: Eye Drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak®
Description: Eye Drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrabak®
Description: Eye Drops
Study: NCT02486822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study: NCT04588753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active isolated stretch
Description: Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Facilitation Stretch
Description: Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs
Study: NCT02298322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting System
Study: NCT01391793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.15 mg/kg/dose twice daily for 3 days
Study: NCT02958111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
Study: NCT00002994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin 2
Description: low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhuMAb
Description: 90 min IV infusion day 7 of each cycle
Study: NCT01690494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT
Description: Couple-based behavioral HIV/STI preventive intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
Study: NCT00847678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efungumab (Mycograb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efungumab (Mycograb)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amphotericin B

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Amphotericin B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amphotericin B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 flucytosine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 5 flucytosine
Study: NCT04000217

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Exposure Therapy
Description: In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal Exposure Therapy
Description: Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
Study: NCT04305145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally
Study: NCT00055315

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
Description: STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study: NCT00113789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PI Discretion
Description: PI Discretion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PI Discretion
Description: PI Discretion
Study: NCT00757874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus cream
Description: 0.5 g per day at bed time for 3 months or less.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol cream
Description: 0.5 gram each day at bed time during 3 months or less.
Study: NCT02293083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trigger point injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trigger point injection
Study: NCT02686333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
Study: NCT01189123

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose influenza vaccine Sanofi-Pasteur
Description: High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fluzone by sanofi pasteur
Description: standard dose fluzone
Study: NCT03576846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and Spinal manipulative therapy
Description: Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
Study: NCT04450043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Run-In Sessions 1-5
Description: Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT Transitions Program Sessions 1-5
Description: Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RCT Control Session
Description: Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
Study: NCT02227251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
Study: NCT03204526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Study: NCT04366232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra alone (stages 2b/3)
Description: Anakinra 300 mg 1/d Intravenous 5 days then dose tapering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra and Ruxolitinib (overcome stage 3)
Description: Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Routine clinical care for Covid-19
Study: NCT03729310

Intervention type: DEVICE
Group type: OTHER
Intervention: Propel 'implant'
Description: The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone
Description: Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopore
Description: This packing' is a sponge-like material which dissolves while releasing triamcinolone.
Study: NCT03727568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies
Study: NCT00893256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: once daily
Study: NCT00719316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300mg per day for 6 weeks
Study: NCT02869646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Acupuncture
Description: Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Procedure: Sham acupuncture
Description: Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
Study: NCT03998865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provisional abutment material
Description: The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provisional abutment material
Description: The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.